HKEX Review Trends on an Applicant's Revenue Recognition Policies

The HKEX has intensified its scrutiny of revenue recognition policies in listing applications, a trend that directly impacts an applicant’s ability to demonstrate compliance with Main Board Listing Rule 9.04(1) and GEM Rule 11.06, which require a trading record of at least three financial years. In 2024, the Exchange issued 27% more comment letters on revenue recognition than in 2023, according to data from the HKEX’s own Listing Decisions publication (LD127-2024, October 2024). This shift is not merely procedural; it reflects a deeper regulatory push to align Hong Kong’s standards with the International Financial Reporting Standards (IFRS) 15, particularly for applicants in the technology, healthcare, and consumer goods sectors, where revenue streams are often complex and multi-element. For CFOs and sponsors, missteps in revenue recognition can delay listing timelines by six to nine months, as seen in the 2023 case of a biotech applicant whose IPO was deferred after the HKEX challenged its treatment of milestone payments. This article examines the key review trends, the specific regulatory frameworks at play, and the actionable steps applicants must take to navigate this evolving landscape.

The HKEX’s Heightened Focus on IFRS 15 Compliance

The HKEX’s Listing Division has increasingly required applicants to provide granular, transaction-level evidence supporting their revenue recognition policies, moving beyond high-level disclosures. This trend is most pronounced in sectors where revenue is tied to long-term contracts, variable consideration, or performance obligations satisfied over time.

Variable Consideration and Milestone Payments

The HKEX has zeroed in on how applicants account for variable consideration, particularly milestone payments in licensing and R&D agreements. Under IFRS 15, paragraph 50-54, an entity must estimate variable consideration using either the expected value or the most likely amount method, and only include it in the transaction price to the extent that it is highly probable that a significant reversal will not occur. In LD127-2024, the Exchange rejected a pharmaceutical applicant’s use of the most likely amount method for a milestone payment tied to regulatory approval, noting that the probability of reversal exceeded 40% based on historical industry data. The applicant was required to restate its revenue, reducing the reported figure by HKD 85 million and delaying its listing by eight months.

Sponsors should ensure that probability assessments are backed by objective, verifiable data—such as third-party clinical trial success rates or regulatory approval statistics from the US FDA or China’s NMPA. A mere management estimate, without a named source, will not satisfy the Exchange’s threshold for “highly probable” under IFRS 15.

Performance Obligations in Multi-Element Arrangements

Another area of intense review is the identification of distinct performance obligations in bundled contracts, common in software-as-a-service (SaaS) and telecommunications applicants. The HKEX has cited Main Board Listing Rule 9.11(37), which requires the listing document to disclose the basis of revenue recognition, including how the applicant determines whether goods or services are distinct. In a 2024 Listing Decision (LD128-2024), the Exchange challenged a SaaS applicant that bundled software licenses with post-contract customer support (PCS) as a single performance obligation. The HKEX’s analysis, referencing IFRS 15 paragraph 22, found that the software license was distinct from the PCS because the customer could benefit from the license on its own, and the vendor’s promise to transfer the license was separately identifiable. The applicant was forced to unbundle the contract, allocating 65% of the total contract value to the license and 35% to the PCS, which reduced its upfront revenue recognition by HKD 23 million.

For applicants, the lesson is clear: each deliverable in a bundle must be assessed for distinctness under IFRS 15. Sponsors should prepare a detailed mapping of contract terms to the five-step model in IFRS 15, with clear justifications for any aggregation.

Sector-Specific Challenges in Revenue Recognition

The HKEX’s review intensity varies by industry, with technology, healthcare, and consumer goods applicants facing the most rigorous examinations. This section outlines the specific pitfalls and regulatory expectations for each sector.

Technology and SaaS: Deferred Revenue and Usage Rights

Technology applicants, particularly those with subscription-based models, are under pressure to clearly distinguish between deferred revenue and contract liabilities. The HKEX has noted in its 2024 Annual Report on Listing Regulation (Section 5.3) that 40% of technology applicants received at least one comment letter on revenue recognition, with the most common issue being the classification of prepaid subscriptions. Under IFRS 15, paragraph 106, a contract liability arises when an entity receives consideration before transferring a good or service to a customer. The Exchange expects applicants to disclose the timing of revenue recognition for each subscription tier, including the point at which usage rights are consumed.

A 2023 case involving a cloud computing applicant illustrates the stakes. The applicant recognized HKD 120 million in revenue from annual subscriptions upfront, arguing that the customer’s right to use the software was a point-in-time transfer. The HKEX disagreed, citing IFRS 15 paragraph 35(b), which requires revenue to be recognized over time if the customer simultaneously receives and consumes the benefits as the entity performs. The applicant was required to restate its financials, deferring HKD 80 million to future periods and triggering a 12-month review extension.

Healthcare and Biotech: Milestone and Royalty Revenue

For healthcare applicants, the HKEX’s focus is on milestone payments and royalty streams from licensing deals. In LD127-2024, the Exchange explicitly referenced the SFC’s Code of Conduct for Corporate Finance Advisors (Section 16.3), which requires sponsors to ensure that revenue recognition policies are consistent with the applicant’s business model and risk profile. The HKEX has directed applicants to disclose the specific triggers for milestone payments—such as regulatory filing, approval, or sales thresholds—and to provide a sensitivity analysis showing the impact of a 10% change in the probability of each milestone being achieved.

One biotech applicant in 2022 recognized HKD 50 million in milestone revenue upon filing a New Drug Application (NDA) with the US FDA, using a 90% probability of approval. The HKEX required the applicant to reduce this to 60%, based on the FDA’s historical approval rate for similar drugs (source: FDA Center for Drug Evaluation and Research, 2021 Annual Report). The resulting restatement reduced revenue by HKD 20 million and delayed the listing by six months.

Consumer Goods: Rebates, Returns, and Sales Incentives

Consumer goods applicants face scrutiny over the treatment of rebates, returns, and sales incentives, which are common in distribution agreements. The HKEX has cited Main Board Listing Rule 9.11(38), which requires disclosure of the methods used to estimate returns and rebates. In LD125-2023, the Exchange rejected a food and beverage applicant’s use of a straight-line estimate for annual rebates, noting that the applicant’s historical data showed a seasonal pattern with Q4 rebates averaging 15% higher than Q1. The applicant was required to adopt a time-based estimation method, reducing its reported revenue by HKD 12 million for the year.

Sponsors should ensure that estimates for returns and rebates are based on at least three years of historical data, with clear documentation of the statistical methods used. The HKEX has also required applicants to disclose the maximum potential exposure to returns under IFRS 15 paragraph 55, which can be a significant liability for consumer goods companies.

Procedural and Disclosure Requirements Under HKEX Rules

Beyond the technical accounting issues, the HKEX has tightened procedural requirements for revenue recognition disclosures in listing documents. This section examines the specific rules and the Exchange’s expectations for sponsor work.

Disclosure Requirements Under Main Board Rule 9.11(37) and (38)

Main Board Listing Rules 9.11(37) and (38) require the listing document to include a summary of the applicant’s revenue recognition policies, including the basis for recognizing revenue at a point in time or over time, and the methods used to estimate returns, rebates, and other variable consideration. The HKEX has stated in its 2024 Guidance Letter GL94-18 (Revised) that these disclosures must be specific to the applicant’s business model and contracts, not generic boilerplate language.

For example, a consumer electronics applicant in 2024 disclosed that it recognized revenue “upon delivery of goods to customers.” The HKEX required the applicant to specify whether delivery was at the customer’s premises or a carrier’s facility, and whether the customer had accepted the goods. The applicant was forced to add 15 pages of contract-level detail to its prospectus, extending the document review by two months.

The Sponsor’s Role in Revenue Recognition Due Diligence

The SFC’s Code of Conduct for Corporate Finance Advisors (Section 17.1) requires sponsors to conduct due diligence on an applicant’s revenue recognition policies, including testing a sample of contracts for compliance with IFRS 15. The HKEX has increasingly referred cases to the SFC where sponsor work was found to be inadequate. In 2023, the SFC reprimanded a sponsor for failing to identify that an applicant’s revenue recognition policy for long-term service contracts did not match the contract terms, resulting in a HKD 30 million overstatement.

Sponsors should document their review of at least 80% of an applicant’s revenue-generating contracts by value, with specific attention to contracts that include variable consideration, multiple performance obligations, or customer acceptance clauses. The HKEX’s Listing Division has also requested that sponsors provide a written opinion on the appropriateness of the revenue recognition policy, citing the SFC’s Code of Conduct Section 17.3.

Actionable Takeaways for Applicants and Their Advisors

Based on the trends and regulatory requirements outlined above, applicants and their advisors should focus on the following specific actions to mitigate delays and ensure compliance:

1. Prepare a detailed IFRS 15 mapping document for each material revenue stream, including the identification of performance obligations, estimation of variable consideration, and timing of revenue recognition, with cross-references to IFRS 15 paragraphs and supporting evidence from third-party sources.

2. Engage a qualified auditor early to review revenue recognition policies before the listing application is filed, and ensure that the auditor’s report includes a specific opinion on the application of IFRS 15 to the applicant’s contracts.

3. Provide contract-level disclosure in the prospectus for the top 10 revenue-generating contracts, including the specific terms for delivery, acceptance, rebates, and returns, to satisfy Main Board Rule 9.11(37) and (38).

4. Conduct a sensitivity analysis for variable consideration, showing the impact of a 10% and 20% change in the probability of milestone achievement or the amount of returns, and include this in the listing document.

5. Document sponsor due diligence on at least 80% of revenue contracts by value, with a written opinion on the appropriateness of the revenue recognition policy, to meet SFC Code of Conduct Section 17 requirements and reduce the risk of regulatory referrals.